Abstract
PURPOSE: We report colon cancer survival rates that are conditioned on patients having already survived one or more years after diagnosis. These rates have more meaning clinically, because they consider those patients who have already survived a given period of time after treatment. METHODS: The life table method was used to compute conditional survival rates, using population-based data obtained from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Patients were diagnosed between 1983 and 1987 and followed up through 1994. Relative and observed survival rates are considered. RESULTS: Survival rates up to ten years after diagnosis are reported by stage of disease, gender, and race for colon cancer patients who survived from one to five years after diagnosis. Survival rates are also reported by lymph node involvement. CONCLUSIONS: Five-year and ten-year survival in colon cancer patients having already survived between one and five years after diagnosis continues to be influenced significantly by stage and race.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Henson DE, Ries LA. On the estimation of survival. Semin Surg Oncol 1994;10:1–5.
Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. Cancer 1995;76:237–42.
Horm JW, Asire AJ, Young JL Jr,et al., eds. Surveillance, epidemiology, and end results program: cancer incidence and mortality in the United States 1973–81. DHHS Publ. No. 85-1837, 1984.
Klawansky S, Burdick E, Adams M,et al. The use of the SEER cancer registry for technology assessment. Int J Technol Assess Health Care 1991;7:134–42.
Ries LA, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards B, eds. SEER cancer statistics review, 1973–1994. National Cancer Institute. NIH Publ. No. 97-2789, 1997.
SEER extent of disease 1983 codes and coding instructions. 1st ed. Bethesda, MD: NIH, May 1988.
Seiffert JE, ed. SEER program comparative staging guide for cancer. NIH Publ. No. 93-3640, 1993.
Beahrs OH, Myers MH. Manual for staging of cancer. 2nd ed. Philadelphia: JB Lippincott, 1983:73–80.
Beahrs OH, Henson DE, Hutter RV, Myers MH. Manual for staging of cancer. 3rd ed. Philadelphia: JB Lippincott, 1988:145–50.
Beahrs OH, Henson DE, Hutter RV, Kennedy BJ. Manual for staging of cancer. 4th ed. Philadelphia: JB Lippincott, 1992:75–9.
Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101–21.
Ries LA, Kosary CL, Lyles BA. Cancer patient survival: why use the relative survival rate. The Abstract 1995;21:28–30.
Henson DE, Ries LA. The relative survival rate. Cancer 1995;76:1687–8.
Percy CL, Stanek E III, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981;71:242–50.
Percy CL, Miller BA, Ries LA. Effect of changes in cancer classification and the accuracy of cancer death certificates on trends in cancer mortality. In: Davis DL, Hoel D, eds. Trends in cancer mortality in industrial countries. New York: New York Academy of Sciences. 1990:609,87–99.
Deans GT, Patterson CC, Parks TG,et al. Colorectal carcinoma: importance of clinical and pathological factors in survival. Ann R Coll Surg Engl 1994;76:59–64.
Roncucci L, Fante R, Losi L,et al. Survival for colon and rectal cancer in a population-based registry. Eur J Cancer 1996;32:295–302.
Sant M, Capocaccia R, Verdecchia A,et al. Comparisons of colon-cancer survival among European countries: The Eurocare Study. Int J Cancer 1995;63:43–8.
Slattery ML, Kerber RA. The impact of family history on colon cancer on survival after diagnosis with colon cancer. Int J Epidemiol 1995;24:888–96.
Gelb AB, Schrock TR. Prognostic factors in colorectal carcinomas. Surg Oncol Clin North Am 1997;6:463–94.
Bumpers HL, Williams WL Jr, Hassett JM Jr,et al. Colon cancer in blacks: age-related presentation and survival within a similar socioeconomic group. J Natl Med Assoc 1994;86:216–8.
Beart RW, Steele GD Jr, Menck HR, Chmiel JS, Ocwieja KE, Winchester DP. Management and survival of patients with adenocarcinoma of the colon and rectum, a national survey of the Commission on Cancer. J Am Coll Surg 1995;181:225–36.
Cooper GS, Yuan Z, Rimm AA. Racial disparity in the incidence and case-fatality of colorectal cancer: analysis of 329 United States counties. Cancer Epidemiol Biomarkers Prev 1997;6:283–5.
Wolters U, Stutzer H, Keller HW, Schroder U, Pichlmaier H. Colorectal cancer: a multivariate analysis of prognostic factors. Eur J Surg Oncol 1996;22:592–7.
Crocetti E, Barchielli A, Buiatti E, Gastiglione G, Zappa M. Colorectal cancer survival: population-based rates in the province of Florence. Eur J Cancer Prev 1996;5:189–95.
Group C status of levamisole. Clinical announcement. National Cancer Institute. US Department of Health and Human Services. April 4, 1989.
National Institutes of Health: Consensus development conference statement: adjuvant therapy for patients with colon and rectum cancer. Bethesda, MD: NIH, April 1990.
Author information
Authors and Affiliations
About this article
Cite this article
Merrill, R.M., Henson, D.E. & Ries, L.A.G. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum 41, 1097–1106 (1998). https://doi.org/10.1007/BF02239430
Issue Date:
DOI: https://doi.org/10.1007/BF02239430